References
- Booth JE, Jacobson JA, Kurrus TA, Edwards TW. Infection of prosthetic arthroplasty by Mycobacterium fortuitum: 2 case reports. J Bone Joint Surg 1979; 61: 300–2
- Horadam VW, Smilack JD, Smith EC. Mycobacterium fortuitum infection after total hip replacement. South Med J 1982; 75: 244–6
- Herold RC, Lotke PA, MacGregor RR. Prosthetic joint infections secondary to rapidly growing Mycobacterium fortuitum. Clin Orthop 1987; 216: 183–6
- Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 1209–25
- Brown-Elliott BA, Wallace RJ, Jr. Infections caused by non-tuberculous mycobacteria. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases6th edn, GL Mandell, JE Bennett, R Dolin. Elsevier Churchill Livingstone, Philadelphia 2005; 2: 2909–16
- Brown-Elliott BA, Wallace RJ, Jr. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716–46
- Hoffman PC, Fraser DW, Robiesek F, O'Bar PR, Mauney CU. Two outbreaks of sternal wound infections due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143: 533–42
- Kuritsky JN, Bullen MG, Broome CV, Silcox VA, Good RC, Wallace RJ, Jr. Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex. Ann Intern Med 1983; 98: 938–9
- Wallace RJ, Jr, Steele LC, Labidi A, Silcox VA. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammoplasty despite case clustering in Texas and other southern coastal states. J Infect Dis 1989; 160: 281–8
- Nolte FS, Metchock B. Mycobacterium. Manual of Medical Microbiology6th edn, P Murray, E Baron, M Pfaller, F Tenover, R Yolken. ASM Press, Washington, D.C 1995; 400–37
- Wallace RJ, Jr, Bedsole G, Sumter G, Sanders CV, Steele LC, Brown BA, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34: 65–70
- Brown BA, Wallace RJ, Jr, Onyi GO, De Rosas V, Wallace RJ III. Activities of 4 macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180–4
- Wallace RJ, Glassroth J, Griffith DE, Olivier KN, Cook JL, Gordin F. American Thoracic Society: diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1–25